CL2011002465A1 - Uso de una fuente de proteina bovina que comprende caseina para mejorar el crecimiento a una edad temprana y/o reducir el riesgo de desarrollo de resistencia a la insulina o diabetes tipo 2 mas adelante en la vida del bebe o nino pequeno - Google Patents

Uso de una fuente de proteina bovina que comprende caseina para mejorar el crecimiento a una edad temprana y/o reducir el riesgo de desarrollo de resistencia a la insulina o diabetes tipo 2 mas adelante en la vida del bebe o nino pequeno

Info

Publication number
CL2011002465A1
CL2011002465A1 CL2011002465A CL2011002465A CL2011002465A1 CL 2011002465 A1 CL2011002465 A1 CL 2011002465A1 CL 2011002465 A CL2011002465 A CL 2011002465A CL 2011002465 A CL2011002465 A CL 2011002465A CL 2011002465 A1 CL2011002465 A1 CL 2011002465A1
Authority
CL
Chile
Prior art keywords
toddler
casein
baby
risk
life
Prior art date
Application number
CL2011002465A
Other languages
English (en)
Inventor
Olivier Aprikian
Florence Mace Catherine Shahkhalili Yassaman Blancher
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40802132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002465(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2011002465A1 publication Critical patent/CL2011002465A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018Hydrolysed proteins; Derivatives thereof from animals from milk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2011002465A 2009-04-03 2011-10-03 Uso de una fuente de proteina bovina que comprende caseina para mejorar el crecimiento a una edad temprana y/o reducir el riesgo de desarrollo de resistencia a la insulina o diabetes tipo 2 mas adelante en la vida del bebe o nino pequeno CL2011002465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09157244 2009-04-03

Publications (1)

Publication Number Publication Date
CL2011002465A1 true CL2011002465A1 (es) 2012-03-23

Family

ID=40802132

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002465A CL2011002465A1 (es) 2009-04-03 2011-10-03 Uso de una fuente de proteina bovina que comprende caseina para mejorar el crecimiento a una edad temprana y/o reducir el riesgo de desarrollo de resistencia a la insulina o diabetes tipo 2 mas adelante en la vida del bebe o nino pequeno

Country Status (15)

Country Link
US (1) US8846612B2 (es)
EP (1) EP2413952B2 (es)
CN (1) CN102378632A (es)
AU (1) AU2010230283B2 (es)
BR (1) BRPI1014065A2 (es)
CA (1) CA2755860A1 (es)
CL (1) CL2011002465A1 (es)
ES (1) ES2570461T5 (es)
MX (1) MX2011010454A (es)
MY (1) MY183275A (es)
PL (1) PL2413952T3 (es)
RU (1) RU2011144581A (es)
SG (1) SG174355A1 (es)
TW (1) TW201039754A (es)
WO (1) WO2010112430A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514435A1 (en) * 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
EP2734049B1 (en) 2011-06-20 2018-05-02 H.J. Heinz Company Brands LLC Probiotic compositions and methods
AU2012373361B2 (en) 2012-03-12 2016-10-27 N.V. Nutricia Process for the humanization of animal skim milk and products obtained thereby
SE1251123A1 (sv) * 2012-10-05 2014-04-06 Indevex Ab Publ Födoämnesprodukt
NZ714202A (en) 2013-05-10 2021-07-30 Heinz Co Brands H J Llc Probiotics and methods of use
WO2015041515A1 (en) * 2013-09-19 2015-03-26 N.V. Nutricia Improved process for the humanization of animal skim milk
CN106231924A (zh) * 2013-11-29 2016-12-14 雀巢产品技术援助有限公司 按年龄定制的具有不同蛋白质含量的营养组合物
EP3082472A1 (en) * 2013-11-29 2016-10-26 Nestec S.A. Infant nutrition for improvement in insulin sensitivity later in life
EP3145333B1 (en) * 2014-05-19 2020-11-04 N.V. Nutricia Infant formula with optimised amino acid profiles
PL3145334T3 (pl) * 2014-05-19 2020-06-01 N.V. Nutricia Formulacje dojelitowe dla przedwcześnie urodzonych niemowląt zawierające zoptymalizowane poziomy przyjmowania fenyloalaniny
WO2016078952A1 (en) * 2014-11-19 2016-05-26 Nestec S.A. Use of whey protein micelles and polysaccharides for improving insulin profile
AU2016267052B2 (en) 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
WO2016196804A1 (en) * 2015-06-04 2016-12-08 Balchem Corporation Hydration control for choline salts
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP4591853A1 (en) 2016-11-21 2025-07-30 Amylyx Pharmaceuticals, Inc. Buffered formulations of exendin (9-39)
MX2019009299A (es) 2017-02-20 2019-09-13 Nestle Sa Composiciones nutricionales con proteinas parcialmente hidrolizadas para el uso en la induccion de respuesta(s) a la glucosa y/o insulina similar(es) a las observadas con leche humana.
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
EP4190324A4 (en) * 2020-07-31 2024-08-14 Otsuka Pharmaceutical Factory, Inc. NUTRITION FORMULATION
EP4561373A1 (en) * 2022-07-29 2025-06-04 Abbott Laboratories Methods for promoting healthy catch-up growth
CN117158379B (zh) * 2023-09-27 2026-04-17 安徽医科大学 一种小鼠孕期宫内生长受限模型及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126474A (en) 1996-04-12 2001-03-19 Beth Israel Hospital Diabetic supplement bar
AUPO272196A0 (en) * 1996-10-02 1996-10-24 Horton, David Robert Filtration apparatus
EP0880902A1 (fr) 1997-05-27 1998-12-02 Nestlé Produkte AG Procédé de traitement d'une matiére première lactosérique
AU771754B2 (en) 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
CA2444470A1 (en) 2001-04-10 2002-10-24 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
JP4440918B2 (ja) 2003-02-10 2010-03-24 ユニバーシティ カレッジ ロンドン 乳児に授乳する人工乳およびシステム
AU2003270130A1 (en) 2003-08-30 2005-03-16 Nestec S.A. Acid soluble proteins from micellar casein
EA200601575A1 (ru) 2004-03-01 2007-06-29 Пептера Фармасьютикалс Лтд. Казеиновые пептиды и их терапевтическое применение
AU2006266546B2 (en) 2005-07-01 2012-01-12 N.V. Nutricia Infant nutrition with hydrolised proteins
PT1940248E (pt) 2005-10-05 2010-01-26 Nestec Sa Utilização de uma composição nutricional para promoção do crescimento acelerado
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
BRPI0706795A2 (pt) * 2006-01-31 2011-04-05 Nestec Sa composição nutricional para bebês com baixo peso de nascimento
DE102006052560B4 (de) 2006-11-06 2010-01-21 Humana Milchunion Eg Anti-diabetogene Calcium-Peptid-Zusammensetzung
EP1932437A1 (en) * 2006-12-15 2008-06-18 Nestec S.A. Infant formula

Also Published As

Publication number Publication date
US20120021977A1 (en) 2012-01-26
EP2413952A1 (en) 2012-02-08
AU2010230283B2 (en) 2015-02-05
ES2570461T3 (es) 2016-05-18
CA2755860A1 (en) 2010-10-07
TW201039754A (en) 2010-11-16
US8846612B2 (en) 2014-09-30
EP2413952B1 (en) 2016-03-23
EP2413952B2 (en) 2019-10-02
SG174355A1 (en) 2011-10-28
ES2570461T5 (es) 2020-04-03
BRPI1014065A2 (pt) 2016-04-12
AU2010230283A1 (en) 2011-10-13
RU2011144581A (ru) 2013-05-10
MX2011010454A (es) 2012-01-25
WO2010112430A1 (en) 2010-10-07
MY183275A (en) 2021-02-18
CN102378632A (zh) 2012-03-14
PL2413952T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2011002465A1 (es) Uso de una fuente de proteina bovina que comprende caseina para mejorar el crecimiento a una edad temprana y/o reducir el riesgo de desarrollo de resistencia a la insulina o diabetes tipo 2 mas adelante en la vida del bebe o nino pequeno
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
CY1123836T1 (el) Κατασκευασματα αυξητικου παραγοντα διαφοροποιησης 15(gdf-15)
MX2016006577A (es) Uso de composiciones nutritivas que tienen una cantidad baja de proteina.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CL2013000594A1 (es) Composicion que comprende hidrolizado de proteina en base lactea que proviene del tratamiento de una solucion de un material proteinaceo de base lactea con al menos una endopeptidasa tipo tripsina, y una endopeptidasa tipo quimotripsina; uso de dicha composicion como fórmula infantil o complemento alimenticio para inducción de tolerancia oral en infantes o pacientes que lo necesitan, o para reducir el riesgo de alergias.
EA201491413A1 (ru) Полипептиды фактора роста и дифференцировки 15 (gdf-15)
GT201500081A (es) Derivados de exendina-4 como agonistas duales de glp1/glucagón
UY35231A (es) Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón
AR091422A1 (es) Analogos peptidicos de la exendina 4
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
CR10290A (es) Metodos para reducir la aglomeracion de proteina
CL2007003584A1 (es) Alimento para animales que utiliza krill como toda o parte de una fuente de proteina del alimento que comprende que se usa krill sin caparazon; y metodo para minimizar la reduccion en la tasa de crecimiento de los peces causada por el uso del krill c
MX2015014007A (es) Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada.
BR112012015597A2 (pt) peptídeos de somatotropina suínos modificados e seus usos
CL2015003634A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112014009225A2 (pt) uso de micelas de proteína de soro de leite para crianças pequenas em risco de obesidade ou diabetes
MX363670B (es) Formulaciones de bromocriptina.
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
AR084495A1 (es) Dispositivo para dormir
ES2452034T5 (es) Composición para el cuidado de prótesis dental
CL2011001734A1 (es) Composición nutricional para infantes que comprende una fuente de proteína, una fuente de lípido y una fuente de carbohidrato, donde la fuente de lípido comprende ácido linoléico y ácido alfa-linolénico